View Older Stories View More Recent Stories
-
Deerfield Management Announces Winners of the First Annual XSeed Award
-
Lumos Pharma to Host Key Opinion Leader Event on LUM-201 for the Treatment of Pediatric Growth Hormone Deficiency
-
Lumos Pharma to Host Key Opinion Leader Event on LUM-201 for the Treatment of Pediatric Growth Hormone Deficiency
-
Endologix LLC Announces Acquisition of PQ Bypass, Inc.
-
Jaguar Gene Therapy Closes $139 Million Series B Funding Co-led by Eli Lilly and Company and Deerfield Management
-
Less Than a Year After Official Company Launch, Cohere Health Lands Additional $36 Million in Series B Funding
-
GH Research Announces Closing of $125 Million Oversubscribed Series B Financing
-
Vesta Healthcare Announces $65M in Growth Capital to Transform Care for High Needs Members and their Caregivers
-
New Report Authored by Deerfield Management Reveals Vast Gender Gap Across Venture-backed Healthcare Companies
-
Dracen Announces DRP-104 (sirpiglenastat) Presentations at AACR Virtual Annual Meeting
-
Deerfield Management, UNC Eshelman School of Pharmacy Announce First Educational Collaboration
-
Terns Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
-
Crossover Health Secures $168 Million in Series D Financing to Fuel Expansion of National Primary Health Service
-
Nuvalent Appoints Christopher Turner, M.D., as Chief Medical Officer
-
Blade Therapeutics Announces Appointment of Jean-Frédéric Viret as Chief Financial Officer
-
Data Presented at ENDO 2021 Differentiate LUM-201 from Standard Growth Hormone Secretagogues and Further Support LUM-201’s Potential as a Therapeutic for Pediatric Growth Hormone Deficiency
-
Data Presented at ENDO 2021 Differentiate LUM-201 from Standard Growth Hormone Secretagogues and Further Support LUM-201’s Potential as a Therapeutic for Pediatric Growth Hormone Deficiency
-
Happify Health Raises $73M to Advance and Expand Digital Health Platform
-
Happify Health Raises $73M to Advance and Expand Digital Health Platform
-
Lumos Pharma Inc. (NASDAQ: LUMO) Featured in Virtual Coverage of the 33rd Annual ROTH Conference
-
Graphite Bio Secures $150 Million Series B Financing to Advance Pipeline of Next-Generation Gene Editing Therapies
-
Nuvation Bio Reports Full Year 2020 Financial Results and Provides Business Update
-
Lumos Pharma to Participate in March 2021 Investor Conferences
-
Lumos Pharma to Participate in March 2021 Investor Conferences
-
Xeris Pharmaceuticals (XERS) Prices $27 Million Registered Direct Offering of Common Stock at $4.12/sh
-
Xeris Pharmaceuticals Announces Pricing of $27.0 Million Registered Direct Offering
-
Lumos Pharma Reports Full Year 2020 Financial Results and Provides Update on OraGrowtH Trials in PGHD
-
Lumos Pharma Reports Full Year 2020 Financial Results and Provides Update on OraGrowtH Trials in PGHD
-
Coridea and Deerfield to Accelerate Medtech Innovation
-
Dracen Announces Clinical Collaboration with Merck
-
Lumos Pharma (LUMO) Says Data Supporting Use of Predictive Enrichment Markers for its LUM-201 Therapy in Clinical Trials for Moderate PGHD Published in Journal of the Endocrine Society
-
Data Supporting Use of Predictive Enrichment Markers for Lumos Pharma’s LUM-201 Therapy in Clinical Trials for Moderate PGHD Published in Journal of the Endocrine Society
-
Data Supporting Use of Predictive Enrichment Markers for Lumos Pharma’s LUM-201 Therapy in Clinical Trials for Moderate PGHD Published in Journal of the Endocrine Society
-
Empire BlueCross BlueShield Partners with On-Demand Healthcare Service Ready to Provide New York City Residents Medical Care in Their Homes
-
Lumos Pharma to Present Poster Demonstrating Greater GH Response to LUM-201 than to Standard GH Secretagogues in PGHD at the Endocrine Society (ENDO) 2021 Annual Meeting
-
Lumos Pharma to Present Poster Demonstrating Greater GH Response to LUM-201 than to Standard GH Secretagogues in PGHD at the Endocrine Society (ENDO) 2021 Annual Meeting
-
FogPharma® Announces $107 Million Series C Financing to Advance Direct β-Catenin Antagonist and Universal Druggability™ Platform
-
Jaguar Gene Therapy Launches with Mission to Accelerate Breakthroughs in Gene Therapy for Patients Suffering from Severe Genetic Diseases
-
Renowned Geneticist Philip Beales Launches Axovia Therapeutics to Develop Transformative Medicines for Ciliopathies
-
Renowned Geneticist Philip Beales Launches Axovia Therapeutics to Develop Transformative Medicines for Ciliopathies
-
Valneva Reports FY 2020 Results and Major Corporate Achievements
-
Valneva Reports FY 2020 Results and Major Corporate Achievements
-
Independence Blue Cross and Quartet Health Collaborate to Address Behavioral Health
-
Xilio Therapeutics Raises $95 Million in Series C Financing to Advance Potent Tumor-Selective Immuno-Oncology Pipeline
-
Lumos Pharma to Report Full Year 2020 Financial Results and Host Conference Call on March 9, 2021
-
Lumos Pharma to Report Full Year 2020 Financial Results and Host Conference Call on March 9, 2021
-
Form 13F-HR DEERFIELD MANAGEMENT For: Dec 31
-
Lumos Pharma Announces Changes to its Board of Directors
-
Lumos Pharma Announces Changes to its Board of Directors
-
Nuvation Bio Closes Transaction with Panacea, Debuts as Publicly Traded Oncology Company

